Compare EARN & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EARN | CRVS |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.7M | 634.0M |
| IPO Year | 2013 | 2016 |
| Metric | EARN | CRVS |
|---|---|---|
| Price | $5.33 | $7.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $5.88 | ★ $13.75 |
| AVG Volume (30 Days) | 309.1K | ★ 1.6M |
| Earning Date | 02-20-2026 | 11-04-2025 |
| Dividend Yield | ★ 18.01% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $35,893,000.00 | N/A |
| Revenue This Year | $8.43 | N/A |
| Revenue Next Year | $17.27 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 43.30 | N/A |
| 52 Week Low | $4.33 | $2.54 |
| 52 Week High | $6.86 | $9.60 |
| Indicator | EARN | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 55.68 | 44.45 |
| Support Level | $5.15 | $7.34 |
| Resistance Level | $5.35 | $8.00 |
| Average True Range (ATR) | 0.10 | 0.52 |
| MACD | 0.01 | -0.12 |
| Stochastic Oscillator | 81.67 | 18.42 |
Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times. The company primary investment objectives are to generate attractive current yields and risk-adjusted total returns for shareholders. It invest in multiple parts of the CLO capital structure, principally mezzanine debt and equity tranches. Rather than focusing only on short-term current yield, it select investments that it believe will provide a strong total return to drive a sustainable earnings stream over a long-term horizon.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).